PROCEPT BioRobotics Co. Director Antal Rohit Desai Sells 25,000 Shares of Stock
| PRCT Stock | USD 49.60 0.36 0.72% |
Slightly above 62% of Procept Biorobotics' investor base is looking to short. The analysis of overall sentiment of trading Procept Biorobotics Corp stock suggests that many investors are alarmed at this time. Procept Biorobotics' investing sentiment can be driven by a variety of factors including economic data, Procept Biorobotics' earnings reports, geopolitical events, and overall market trends.
PROCEPT BioRobotics Co. Director Antal Rohit Desai sold 25,000 shares of the firms stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of 63.91, for a total transaction of 1,597,750.00. Following the sale, the director now owns 64,363 shares in the company, valued
Read at thelincolnianonline.com
 |
Procept Biorobotics Fundamental Analysis
We analyze Procept Biorobotics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Procept Biorobotics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Procept Biorobotics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Procept Biorobotics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Procept Biorobotics Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Procept Biorobotics stock to make a market-neutral strategy. Peer analysis of Procept Biorobotics could also be used in its relative valuation, which is a method of valuing Procept Biorobotics by comparing valuation metrics with similar companies.
Peers
Procept Biorobotics Related Equities
| TYRA | Tyra Biosciences | 7.51 | ||||
| SGHT | Sight Sciences | 6.12 | ||||
| PROF | Profound Medical | 3.45 | ||||
| SIBN | Si Bone | 2.93 | ||||
| NUVL | Nuvalent | 0.34 | ||||
| TMCI | Treace Medical | 0.36 |
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.